PDL BioPharma Profile

2.79
USD 0.04  1.45%
26%
2.93
93%
2.795

Acquisition by John McLaughlin of 129201 shares of PDL BioPharma subject to Rule 16b-3

PDL BioPharma Inc insider trading alert for grant of common stock by John McLaughlin, President CEO, on January 8, 2018. This event was filed by Pdl Biopharma Inc with SEC on 2015-01-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

PDL BioPharma Summary

PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.? Their market capitalization is $365 million and the stock is trading at $2.20 per share. ? Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.? Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.? They are a middleman for the pharma patent industry. ? ? [more]
PDL BioPharma Inc (PDLI) is traded on NASDAQ in USA. It is located in NEVADA, U.S.A and employs 10 people. PDL BioPharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 438.32 M. PDL BioPharma Inc has 154.34 M outstanding shares of which 19.07 M shares are at this time shorted by private and institutional investors with about 9.16 trading days to cover. PDL BIOPHARMA INC currently holds about 516.49 M in cash with 73.72 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.35 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PDL BioPharma Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Acadian Asset Management LlcCommon Shares5.3 M14.5 M
Schwab Charles Investment Management IncCommon Shares3.1 M8.6 M
Benjamin F Edwards Company IncDebt10 K10 K
Simplex Trading LlcCall Options1471000
Simplex Trading LlcPut Options22.00.0
View PDL BioPharma Diagnostics

Selected PDL BioPharma Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

PDL BioPharma Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 46% 
Equity ratings for PDL BioPharma Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NamePDL BioPharma Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationNEVADA, U.S.A
Business Address932 Southwood Boulevard, Incline Village, NV 89451, United States
ExchangeNASDAQ
CIK Number00882104.0
CUSIP69329Y104
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.pdl.com
Contact Number775 832 8500
CurrencyUSD - US Dollar

Recommendations

PDL BioPharma Analyst Recommendations
Target PriceAdvice# of Analysts
3.5Buy2Odds
PDL BioPharma Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
PDL BioPharma Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

PDL BioPharma Earnings Estimates
EPSEstimate Date
Quarterly Estimate0.13March 1, 2017
PDL BioPharma Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate